All In Biotech

Drug Trial Radar · NCT05041790

A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IV Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment(ESCALADE)

Last checked: Nov 20, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 418 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

418

Planned (sponsor's estimate)

Start

Sep 30, 2021

Primary completion

Nov 30, 2024

Study completion Nov 30, 2024

Sponsor

Lead sponsor
Chong Kun Dang PharmaceuticalIndustry
Sponsor type
Industry
Collaborators
Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)
First posted
Sep 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in patients with degenerative mild cognitive impairment.

Conditions

  • Mild Cognitive Impairment

Interventions

  • Choline AlfoscerateDrug

    Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.

  • PlaceboDrug

    Placebo of Choline Alfoscerate 400mg per oral 3 times a day during the entire treatment period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects whose cognitive function is maintained/improved at 48 weeks compared to baselineTime frame: Baseline to 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center Institutional Review Board

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.